Lilly names new head of late-phase oncology development

Lilly has announced the appointment of Dr Maura Dickler as vice-president of late-phase development at Lilly Oncology, effective as of May 7th.

Dr Dickler is a renowned breast cancer researcher who currently serves as section head for endocrine therapy clinical research at the Memorial Sloan Kettering Cancer Center in New York.

Her research focuses on developing new therapeutic strategies for the treatment of women with hormone receptor-positive breast cancer, and has led clinical trials investigating therapeutic agents targeting several pathways important in breast cancer.

With numerous pieces of research published, Dr Dinkler has also received a number of honours for her work in clinical care, being named by New York Magazine as one of the best doctors in the medical oncology field in 2015, 2016 and 2017.

Dr Levi Garraway, senior vice-president for global development and medical affairs at Lilly Oncology, said: "Dr Dickler is an internationally recognised oncology leader with drug development expertise spanning a wide range of therapeutic modalities. Moreover, she is an exceptionally gifted clinician for whom patients are at the centre of everything she does."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.